Bajaj Healthcare Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The acquisition, valued at Rs 10.85 crore through a cash consideration, involves 100% control of Genrx Pharmaceuticals.

GenRx Pharmaceuticals is a WHO-GMP certified pharmaceutical manufacturer engaged in the production of allopathic formulations, nutraceuticals, and natural products. The company operates a manufacturing facility located at MIDC Sinnar, Nashik, with the capability to produce solid and semi-solid dosage forms such as tablets, capsules, external preparations, cosmetic products, and nasal sprays.

Anil Jain, managing director, Bajaj Healthcare, said: ?The acquisition of Genrx Pharmaceuticals marks a strategic step forward in expanding our formulations manufacturing capabilities.

This aligns with our vision of strengthening our core business and leveraging synergies for accelerated growth. Completion of the acquisition is expected within 3?6 months, subject to requisite FDA and other regulatory approvals.

This addition will enable us to expand our manufacturing portfolio, paving the way for long-term value creation and strengthening our footprint in the pharmaceutical sector.

Bajaj Healthcare a leading manufacturer of apis, intermediates and formulations. It specializes in manufacturing of intermediates, API, formulations & nutraceuticals.

Powered by Capital Market - Live News

Net profit of Bajaj Healthcare reported to Rs 11.72 crore in the quarter ended December 2024 as against net loss of Rs 2.20 crore during the previous quarter ended December 2023. Sales rose 13.10% to Rs 122.79 crore in the quarter ended December 2024 as against Rs 108.57 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 11 February 2025.

Powered by Capital Market - Live News

Net profit of Bajaj Healthcare reported to Rs 11.72 crore in the quarter ended December 2024 as against net loss of Rs 2.20 crore during the previous quarter ended December 2023. Sales rose 13.10% to Rs 122.79 crore in the quarter ended December 2024 as against Rs 108.57 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 11 February 2025.

Powered by Capital Market - Live News

Pimavanserin is an atypical antipsychotic used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Pimavanserin, marketed globally as NUPLAZID, has become a preferred treatment in the US antipsychotic segment.

In a recent update, Acadia Pharmaceuticals announced that NUPLAZID, along with its other brand DAYBUE, is projected to generate more than $1 billion in net sales in 2025.

The company has also extended offer for manufacturing of Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product’s availability in the domestic market.

Anil Jain, managing director, Bajaj Healthcare, said: “The approval marks a major milestone for Bajaj Healthcare.

The growing success of NUPLAZID in the US underscores the global demand for this innovative therapy, and we are confident that its introduction in India will be a transformative advancement in the antipsychotic segment.

This move further solidifies our presence in the central nervous system (CNS) segment and highlights our dedication to advancing healthcare solutions in India.”

Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

The company had reported standalone net profit of Rs 94.64 crore in Q2 FY25 as compared with net loss of Rs 34.60 crore in Q2 FY24. Revenue from operations jumped 31.5% YoY to Rs 133.08 crore in Q2 FY25.

The scrip fell 2.46% to currently trade at Rs 640.25 on the BSE.

Powered by Capital Market - Live News

The acquisition, valued at Rs 10.85 crore through a cash consideration, involves 100% control of Genrx Pharmaceuticals.

GenRx Pharmaceuticals is a WHO-GMP certified pharmaceutical manufacturer engaged in the production of allopathic formulations, nutraceuticals, and natural products. The company operates a manufacturing facility located at MIDC Sinnar, Nashik, with the capability to produce solid and semi-solid dosage forms such as tablets, capsules, external preparations, cosmetic products, and nasal sprays.

Anil Jain, managing director, Bajaj Healthcare, said: ?The acquisition of Genrx Pharmaceuticals marks a strategic step forward in expanding our formulations manufacturing capabilities.

This aligns with our vision of strengthening our core business and leveraging synergies for accelerated growth. Completion of the acquisition is expected within 3?6 months, subject to requisite FDA and other regulatory approvals.

This addition will enable us to expand our manufacturing portfolio, paving the way for long-term value creation and strengthening our footprint in the pharmaceutical sector.

Bajaj Healthcare a leading manufacturer of apis, intermediates and formulations. It specializes in manufacturing of intermediates, API, formulations & nutraceuticals.

Powered by Capital Market - Live News

Net profit of Bajaj Healthcare reported to Rs 11.72 crore in the quarter ended December 2024 as against net loss of Rs 2.20 crore during the previous quarter ended December 2023. Sales rose 13.10% to Rs 122.79 crore in the quarter ended December 2024 as against Rs 108.57 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 11 February 2025.

Powered by Capital Market - Live News

Net profit of Bajaj Healthcare reported to Rs 11.72 crore in the quarter ended December 2024 as against net loss of Rs 2.20 crore during the previous quarter ended December 2023. Sales rose 13.10% to Rs 122.79 crore in the quarter ended December 2024 as against Rs 108.57 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 11 February 2025.

Powered by Capital Market - Live News

Pimavanserin is an atypical antipsychotic used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Pimavanserin, marketed globally as NUPLAZID, has become a preferred treatment in the US antipsychotic segment.

In a recent update, Acadia Pharmaceuticals announced that NUPLAZID, along with its other brand DAYBUE, is projected to generate more than $1 billion in net sales in 2025.

The company has also extended offer for manufacturing of Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product’s availability in the domestic market.

Anil Jain, managing director, Bajaj Healthcare, said: “The approval marks a major milestone for Bajaj Healthcare.

The growing success of NUPLAZID in the US underscores the global demand for this innovative therapy, and we are confident that its introduction in India will be a transformative advancement in the antipsychotic segment.

This move further solidifies our presence in the central nervous system (CNS) segment and highlights our dedication to advancing healthcare solutions in India.”

Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

The company had reported standalone net profit of Rs 94.64 crore in Q2 FY25 as compared with net loss of Rs 34.60 crore in Q2 FY24. Revenue from operations jumped 31.5% YoY to Rs 133.08 crore in Q2 FY25.

The scrip fell 2.46% to currently trade at Rs 640.25 on the BSE.

Powered by Capital Market - Live News